Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein
Rift Valley fever is a viral haemorrhagic disease first discovered in Kenya in 1930. Numerous animal studies have demonstrated that protective immunity is acquired following Rift Valley fever virus infection and that this correlates with acquisition of virus-neutralizing antibodies that target the viral envelope glycoproteins. However, naturally acquired immunity to Rift Valley fever in humans is poorly described. This research paper characterized the immune response to the viral envelope glycoproteins, Gn and Gc, in Rift Valley fever-exposed Kenyan adults.